NIH VideoCast - Cancer Immunotherapy by Targeting Unique Cancer Mutations

Skip Navigation

Cancer Immunotherapy by Targeting Unique Cancer Mutations

Loading... Loading video...

910 Views

Air date:	Wednesday, April 29, 2015, 4:15:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 910 (119 Live, 791 On-demand)
Category:	Immunology
Runtime:	01:04:56
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	Immunology Interest Group Dr. Steve Rosenberg received his B.A. and M.D. degrees at Johns Hopkins University and a Ph.D. in Biophysics at Harvard University. After completing his residency training in surgery in 1974 at the Peter Bent Brigham Hospital in Boston, Massachusetts, Dr. Rosenberg became the Chief of Surgery at the NCI, NIH, a position he has held to the present time. Dr. Rosenberg has pioneered the development of effective immunotherapies and gene therapies for patients with advanced cancers. His studies of the adoptive transfer of genetically modified lymphocytes have resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas. His current research is aimed at defining the host immune response of patients to their cancers. These studies emphasize the ability of human lymphocytes to recognize unique cancer antigens and the identification of anti-tumor T cell receptors that can be exploited to develop new cell transfer immunotherapies for the treatment of cancer patients. Dr. Rosenberg also oversees the Surgery Branch’s clinical program aimed at translating scientific advances into effective immunotherapies for patients with cancer. For more information go to http://sigs.nih.gov/immunology/Pages/default.aspx

NLM Title:	Cancer immunotherapy by targeting unique cancer mutations / Steven Rosenberg ; Immunology Interest Group.
Author:	Rosenberg, Steven A. National Institutes of Health (U.S.). Immunology Interest Group,
Publisher:
Abstract:	(CIT): Dr. Steve Rosenberg received his B.A. and M.D. degrees at Johns Hopkins University and a Ph.D. in Biophysics at Harvard University. After completing his residency training in surgery in 1974 at the Peter Bent Brigham Hospital in Boston, Massachusetts, Dr. Rosenberg became the Chief of Surgery at the NCI, NIH, a position he has held to the present time. Dr. Rosenberg has pioneered the development of effective immunotherapies and gene therapies for patients with advanced cancers. His studies of the adoptive transfer of genetically modified lymphocytes have resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas. His current research is aimed at defining the host immune response of patients to their cancers. These studies emphasize the ability of human lymphocytes to recognize unique cancer antigens and the identification of anti-tumor T cell receptors that can be exploited to develop new cell transfer immunotherapies for the treatment of cancer patients. Dr. Rosenberg also oversees the Surgery Branch"s clinical program aimed at translating scientific advances into effective immunotherapies for patients with cancer.
Subjects:	Immunotherapy--methods Neoplasms--therapy
Publication Types:	Lecture Webcast

NLM Classification:	QZ 266
NLM ID:	101658209
CIT Live ID:	16218
Permanent link:	https://videocast.nih.gov/watch=16218

Related Videos...